Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.